Aligos Therapeutics (NASDAQ:ALGS) Upgraded to “Strong-Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Aligos Therapeutics (NASDAQ:ALGS) to a strong-buy rating in a research report report published on Friday morning,Zacks reports.

A number of other brokerages also recently commented on ALGS. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $45.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Aligos Therapeutics Trading Down 0.7%

Shares of ALGS opened at $5.51 on Friday. The firm has a fifty day moving average price of $5.75 and a 200-day moving average price of $6.13. The firm has a market capitalization of $34.38 million, a P/E ratio of -0.75 and a beta of 2.34. Aligos Therapeutics has a 12-month low of $3.98 and a 12-month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.95. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The company had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Analysts predict that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ALGS. Rockefeller Capital Management L.P. raised its holdings in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after purchasing an additional 15,006 shares in the last quarter. SummitTX Capital L.P. boosted its stake in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after buying an additional 216,646 shares during the period. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.

Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression.